Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30179% above fair value
$26.68+0.48 (+1.83%)
Close on Nov 13, 2026Market cap $1.72BP/E –Yield –
Stoke Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Stoke Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -809.7%. For fiscal 2025 it was -11.2%, against -277.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -11.2% | +266.1 |
| FY2024 | Dec 31, 2024 | -277.3% | +1029.9 |
| FY2023 | Dec 31, 2023 | -1307.2% | −466.0 |
| FY2022 | Dec 31, 2022 | -841.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -701.7% | −504.1 |
| Q1 FY2026 | Mar 31, 2026 | -857.6% | −927.7 |
| Q4 FY2025 | Dec 31, 2025 | -4382.2% | −4321.9 |
| Q3 FY2025 | Sep 30, 2025 | -405.3% | +207.8 |
| Q2 FY2025 | Jun 30, 2025 | -197.6% | +409.8 |
| Q1 FY2025 | Mar 31, 2025 | 70.2% | +743.1 |
| Q4 FY2024 | Dec 31, 2024 | -60.4% | +995.5 |
| Q3 FY2024 | Sep 30, 2024 | -613.1% | +210.2 |
| Q2 FY2024 | Jun 30, 2024 | -607.4% | −128.1 |
| Q1 FY2024 | Mar 31, 2024 | -673.0% | +158.6 |
| Q4 FY2023 | Dec 31, 2023 | -1055.9% | −121.4 |
| Q3 FY2023 | Sep 30, 2023 | -823.3% | −42.2 |
| Q1 FY2023 | Mar 31, 2023 | -479.2% | +347.3 |
| Q4 FY2022 | Dec 31, 2022 | -831.6% | – |
| Q3 FY2022 | Sep 30, 2022 | -934.5% | – |
| Q2 FY2022 | Jun 30, 2022 | -781.1% | – |
| Q1 FY2022 | Mar 31, 2022 | -826.5% | – |
See a number that looks wrong?